Takeda Pharmaceutical Company Limited in 3 stories
The narratives 4502.T currently appears in, with its side and exposure in each.
Bull side
1 story- China Becomes Pharma's Global R&D Engine
4502.T in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Takeda has successfully sourced Chinese-developed medicines through its global rights to HUTCHMED's fruquintinib and its option agreement for Ascentage's olverembatinib.
Bear side
2 stories- America Imports the World's Drug Prices
4502.T in “America Imports the World's Drug Prices”
StableExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Takeda derives substantial revenue from globally sold specialty drugs and would face reduced lifetime product value from tighter cross-market price linkage.
- The Patent Cliff Sparks a Biotech Land Grab
4502.T in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yetLarge drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Takeda must manage exclusivity losses and debt while finding enough new products to sustain its global revenue base.